Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Epstein-barr virus-related post-transplant lymphoproliferative disorder in a renal transplant recipient treated with tacrolimus and antithymocyte globulin.

Literature DB >> 17535041

Epstein-barr virus-related post-transplant lymphoproliferative disorder in a renal transplant recipient treated with tacrolimus and antithymocyte globulin.

Agnes L F Chan¹, Hue-Yu Wang.

Abstract

Entities: Chemical Disease Species

Year: 2003 PMID： 17535041 DOI： 10.2165/00044011-200323040-00008

Source DB: PubMed Journal: Clin Drug Investig ISSN： 1173-2563 Impact factor: 2.859

× No keyword cloud information.

17 in total

1. Post-transplantation lymphoproliferative disorder: an unusual presentation in a patient receiving tacrolimus.

Authors: H Gallagher; J T Kwan; P A Andrews
Journal: Nephrol Dial Transplant Date: 2000-06 Impact factor: 5.992

2. Posttransplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus infection and immunosuppression.

Authors: K A Newell; E M Alonso; P F Whitington; D S Bruce; J M Millis; J B Piper; E S Woodle; S M Kelly; H Koeppen; J Hart; C M Rubin; J R Thistlethwaite
Journal: Transplantation Date: 1996-08-15 Impact factor: 4.939

3. Epstein-Barr virus-related disorders in children undergoing renal transplantation with tacrolimus-based immunosuppression.

Authors: D Ellis; R Jaffe; M Green; J J Janosky; S Lombardozzi-Lane; R Shapiro; V Scantlebury; C Vivas; M L Jordan
Journal: Transplantation Date: 1999-10-15 Impact factor: 4.939

4. Posttransplant lymphoproliferative disease in primary Epstein-Barr virus infection after liver transplantation: the role of cytomegalovirus disease.

Authors: R Mañez; M C Breinig; P Linden; J Wilson; J Torre-Cisneros; S Kusne; S Dummer; M Ho
Journal: J Infect Dis Date: 1997-12 Impact factor: 5.226

5. Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus.

Authors: E M Sokal; H Antunes; C Beguin; M Bodeus; P Wallemacq; J de Ville de Goyet; R Reding; M Janssen; J P Buts; J B Otte
Journal: Transplantation Date: 1997-11-27 Impact factor: 4.939

Review 6. Posttransplantation lymphoproliferative disorder in patients under primary tacrolimus (FK 506) immunosuppression.

Authors: D G Deschler; R Osorio; N L Ascher; K C Lee
Journal: Arch Otolaryngol Head Neck Surg Date: 1995-09

7. Lymphoproliferative disorders after organ transplantation: a report of 24 cases observed in a single center.

Authors: V Leblond; L Sutton; R Dorent; F Davi; M O Bitker; J Gabarre; F Charlotte; J J Ghoussoub; C Fourcade; A Fischer
Journal: J Clin Oncol Date: 1995-04 Impact factor: 44.544

8. Conversion from cyclosporine to FK506 for salvage of immunocompromised pediatric liver allografts. Efficacy, toxicity, and dose regimen in 23 children.

Authors: R Reding; P E Wallemacq; M E Lamy; J Rahier; C Sempoux; B Debande; J Jamart; A Barker; E Sokal; J De Ville de Goyet
Journal: Transplantation Date: 1994-01 Impact factor: 4.939